BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31408027)

  • 1. Pyoderma Gangrenosum Associated with Sunitinib: A Case Report.
    Sevimli Dikicier B
    Adv Skin Wound Care; 2019 Sep; 32(9):427-429. PubMed ID: 31408027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib-induced pyoderma gangrenosum-like skin ulcer.
    Kuntz T; Koushk-Jalali B; Kreuter A
    CMAJ; 2020 May; 192(20):E552. PubMed ID: 32452467
    [No Abstract]   [Full Text] [Related]  

  • 3. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
    Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
    Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute sunitinib neurotoxicity.
    Gulmez A; Dikilitas M; Elkiran ET; Harputluoglu H
    Cancer Treat Res Commun; 2021; 27():100366. PubMed ID: 33812180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib induced pyoderma gangrenosum-like ulcerations.
    Akanay-Diesel S; Hoff NP; Kürle S; Haes J; Erhardt A; Häussinger D; Schulte KW; Bölke E; Matuschek C; Budach W; Gerber PA; Homey B
    Eur J Med Res; 2011 Nov; 16(11):491-4. PubMed ID: 22027642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Induced Pyoderma Gangrenosum: A Review.
    Wang JY; French LE; Shear NH; Amiri A; Alavi A
    Am J Clin Dermatol; 2018 Feb; 19(1):67-77. PubMed ID: 28624960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of pyoderma gangrenosum induced by insulin.
    Noronha M; Arora S; Pai K; Sathish Pai B; Jindal A
    Int Wound J; 2019 Oct; 16(5):1239-1242. PubMed ID: 31353778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.
    Wu BC; Patel ED; Ortega-Loayza AG
    Br J Dermatol; 2017 Jul; 177(1):72-83. PubMed ID: 27864925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
    Medioni J; Cojocarasu O; Belcaceres JL; Halimi P; Oudard S
    Ann Oncol; 2007 Jul; 18(7):1282-3. PubMed ID: 17675397
    [No Abstract]   [Full Text] [Related]  

  • 12. [Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies)].
    Boulenger-Vazel A; Kupfer-Bessaguet I; Gouedard C; Leberre R; Leroy JP; Sonnet E; Desvignes O; Misery L; Sassolas B
    Ann Dermatol Venereol; 2005 Jan; 132(1):27-31. PubMed ID: 15746603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
    ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
    Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
    [No Abstract]   [Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports.
    Khoshnam-Rad N; Gheymati A; Jahangard-Rafsanjani Z
    Anticancer Drugs; 2022 Jan; 33(1):e1-e8. PubMed ID: 34282745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pyoderma gangrenosum associated with anti-proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) induced by propylthiouracil].
    Coster A; Dargent JL; de Visscher N; Levecque P; Roquet-Gravy PP
    Ann Dermatol Venereol; 2017 May; 144(5):368-373. PubMed ID: 28291538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophilic dermatoses: a review of current treatment options.
    Cohen PR
    Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions.
    Sagara R; Kitami A; Nakada T; Iijima M
    Int J Dermatol; 2006 Aug; 45(8):1002-3. PubMed ID: 16911406
    [No Abstract]   [Full Text] [Related]  

  • 18. Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome.
    Takagi S; Ohsaka A; Taguchi H; Kusama H; Matsuoka T
    Intern Med; 1998 Mar; 37(3):316-9. PubMed ID: 9617871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma.
    Mir-Bonafé JM; Cañueto J; Bravo J; de Unamuno P
    Int J Dermatol; 2013 Nov; 52(11):1445-7. PubMed ID: 23432117
    [No Abstract]   [Full Text] [Related]  

  • 20. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia.
    Montoto S; Bosch F; Estrach T; Blade J; Nomdedeu B; Nontserrat E
    Leuk Lymphoma; 1998 Jun; 30(1-2):199-202. PubMed ID: 9669691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.